Download PDF
Der Nuklearmediziner 2007; 30(3): 204-211
DOI: 10.1055/s-2007-981215
Nuklearmedizinische Gehirndiagnostik

© Georg Thieme Verlag Stuttgart · New York

Hirntumoren

Brain TumorsK.-J. Langen1 , G. Stoffels2
  • 1Institut für Neurowissenschaften und Biophysik - Medizin, Forschungszentrum Jülich
  • 2C. & O. Vogt Institut für Hirnforschung, Heinrich-Heine-Universität Düsseldorf
Further Information

Publication History

Publication Date:
31 August 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die morphologische Bildgebung mit der Magnetresonanztomografie (MRT) ist heute das Verfahren der Wahl zur Diagnostik von Hirntumoren, erlaubt jedoch in vielen Situationen nur eine eingeschränkte Differenzierung des Tumorgewebes von unspezifischen Gewebsveränderungen. Die Positronen-Emissions-Tomografie (PET) und Single-Photonen-Emissions-Tomografie (SPECT) haben sich als leistungsfähige diagnostische Verfahren erwiesen, die bei unklaren Befunden in vielen Fällen zu einer weiteren Abklärung beitragen können. Insbesondere die Bildgebung mit Aminosäuren führt bei zerebralen Gliomen zu einer spezifischeren Darstellung der Ausdehnung des soliden Gliomgewebes, welche bei der Planung einer Biopsie, eines neurochirurgischen Eingriffs und einer Bestrahlung entscheidende Hilfestellung bieten kann. Des Weiteren können Tumorrezidive von posttherapeutischen Veränderungen besser differenziert, wertvolle prognostische Informationen bei niedriggradigen Gliomen gewonnen und Therapieeffekte frühzeitig beurteilt werden.

Abstract

Magnetic Resonance Tomography (MRT) is the method of choice for the diagnostics of cerebral gliomas, but the differentiation of tumour tissue from unspecific tissue changes is limited. Positron emission tomography (PET) and Single-Photon-Emission-Computed Tomography (SPECT) may offer relevant additional information which allows for a more accurate diagnostics in unclear situations. Especially, radiolabeled amino acids offer a better delineation of cerebral gliomas which allows an improved guidance of biopsy, planning of surgery and radiation therapy. Furthermore, amino acid imaging appears to be useful to differentiate tumor recurrence from unspecific posttherapeutic tissue, to predict the prognosis especially in low grade gliomas and to monitor the metabolic response during tumor therapy.

Schlüsselwörter

PET - SPECT - Hirntumoren - FDG - Aminosäuren - 201Tl - 99mTc-Sestamibi - 99mTc-Tetrofosmin

Key words

PET - SPECT - brain tumors - FDG - amino acids - 201Tl - 99mTc-Sestamibi - 99mTc-Tetrofosmin

Literatur

  • 1 Beauchesne P, Pedeux R, Boniol M, Soler C. 99mTc-Sestamibi brain SPECT after chemoradiotherapy is prognostic of survival in patients with high-grade glioma.  J Nucl Med. 2004;  45 409-413
    PubMedSearch in Google Scholar
  • 2 Chaskis C, Stadnik T, Michotte A, Van Rompaey K, D’Haens J. Prognostic value of perfusion-weighted imaging in brain glioma: a prospective study.  Acta Neurochir. 2006;  148 277-285
    CrossrefPubMedSearch in Google Scholar
  • 3 Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps M E, Silverman D H. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.  J Nucl Med. 2005;  46 945-952
    PubMedSearch in Google Scholar
  • 4 Cher L M, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, O’Keefe G J, Sachinidis J I, Berlangieri S U, Fabinyi G, Scott A M. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.  J Nucl Med. 2006;  47 410-418
    PubMedSearch in Google Scholar
  • 5 Choi J Y, Kim S E, Shin H J, Kim B T, Kim J H. Brain tumor imaging with 99mTc-tetrofosmin: comparison with 201Tl, 99mTc-MIBI, and 18F-fluorodeoxyglucose.  J Neurooncol. 2000;  46 63-70
    CrossrefPubMedSearch in Google Scholar
  • 6 De Herder W W, Reijs A E, Feelders R A, van Aken M O, Krenning E P, van der Lely A J, Kwekkeboom D J. Diagnostic imaging of dopamine receptors in pituitary adenomas.  Eur J Endocrinol. 2007;  156 Suppl 1 53-56
    CrossrefPubMedSearch in Google Scholar
  • 7 Del Sole A, Falini A, Ravasi L, Ottobrini L, De Marchis D, Bombardieri E, Lucignani G. Anatomical and biochemical investigation of primary brain tumours.  Eur J Nucl Med. 2001;  28 1851-1872
    CrossrefPubMedSearch in Google Scholar
  • 8 Derlon J M. The in vivo metabolic investigation of brain gliomas with positron emission tomography.  Adv Tech Stand Neurosurg. 1998;  24 Review 41-76
    PubMedSearch in Google Scholar
  • 9 Ernst S. Hirntumoren. In: Heindel W, Kugel H, Lackner K (eds). Rationelle MR-Untersuchungstechniken. Thieme Verlag Stuttgart 1997; 3-7
  • 10 Floeth F, Pauleit D, Wittsack H J, Langen K J, Reifenberger G, Hamacher K, Müller H W, Zilles K, Messing-Jünger M, Weber F, Stummer W, Steiger H J, Coenen H H, Sabel M. Multimodal metabolic imaging of cerebral gliomas using positron emission tomography with [18F]-fluoroethyl-l-tyrosine and magnetic resonance spectroscopy.  J Neurosurgery. 2005;  102 318-327
    CrossrefPubMedSearch in Google Scholar
  • 11 Floeth F W, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider M J, Jansen P, Hamacher K, Coenen H H, Stummer W, Steiger H J, Langen K J. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.  J Nucl Med. 2007;  48 519-527
    CrossrefPubMedSearch in Google Scholar
  • 12 Galldiks N, Kracht L W, Burghaus L, Thomas A, Jacobs A H, Heiss W D, Herholz K. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.  Eur J Nucl Med Mol Imaging. 2006;  33 516-524
    CrossrefPubMedSearch in Google Scholar
  • 13 Gomez-Rio M, Martinez Del Valle Torres D, Rodriguez-Fernandez A, Llamas-Elvira J M, Lozano S O, Font C R, Lopez Ramirez E, Katati M. (201)Tl-SPECT in low-grade gliomas: diagnostic accuracy in differential diagnosis between tumour recurrence and radionecrosis.  Eur J Nucl Med Mol Imaging. 2004;  31 1237-1243
    PubMedSearch in Google Scholar
  • 14 Grosu A L, Feldmann H, Dick S. et al . Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas.  Int J Radiat Oncol Biol Phys. 2002;  54 842-854
    CrossrefPubMedSearch in Google Scholar
  • 15 Grosu A L, Weber W A, Franz M, Stark S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C. Reirradiation of recurrent high-grade gliomas using amino acid PET(SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.  Int J Radiat Oncol Biol Phys. 2005;  63 511-519
    CrossrefPubMedSearch in Google Scholar
  • 16 Henze M, Mohammed A, Schlemmer H P, Herfarth K K, Hoffner S, Haufe S, Mier W, Eisenhut M, Debus J, Haberkorn U. PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis.  J Nucl Med. 2004;  45 579-586
    PubMedSearch in Google Scholar
  • 17 Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss L G, Doll J, Macke H R, Eisenhut M, Debus J, Haberkorn U. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.  J Nucl Med. 2005;  46 763-769
    PubMedSearch in Google Scholar
  • 18 Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Ernestus R I, Mendoza G, Weber-Luxemburger G, Löttgen J, Thiel A, Wienhard K Heiss W D. 11C-methionine PET for differential diagnosis of low-grade-gliomas.  Neurology. 1998;  50 1316-1322
    CrossrefPubMedSearch in Google Scholar
  • 19 Jacobs A H, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, Kaestle C, Wagner R, Wienhard K, Heiss W D. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas.  Lancet. 2001;  358 727-729
    CrossrefPubMedSearch in Google Scholar
  • 20 Jacobs A H, Kracht L W, Gossmann A. et al . Imaging in neurooncology.  NeuroRx. 2005;  2 Review 333-347
    CrossrefPubMedSearch in Google Scholar
  • 21 Jacobs A H, Thomas A, Kracht L W, Li H, Dittmar C, Garlip G, Galldiks N, Klein J C, Sobesky J, Hilker R, Vollmar S, Herholz K, Wienhard K, Heiss W D. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.  J Nucl Med. 2005;  46 1948-1958
    PubMedSearch in Google Scholar
  • 22 Jager P L, Vaalburg W, Pruim J, de Vries E G, Langen K J, Piers D A. Radiolabeled amino acids: basic aspects and clinical applications in oncology.  J Nucl Med. 2001;  42 432-445
    PubMedSearch in Google Scholar
  • 23 Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G. et al . Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.  J Nucl Med. 1998;  39 778-785
    PubMedSearch in Google Scholar
  • 24 Kracht L W, Miletic H, Busch S, Jacobs A H, Voges J, Hoevels M, Klein J C, Herholz K, Heiss W D. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology.  Clin Cancer Res. 2004;  10 7163-7170
    CrossrefPubMedSearch in Google Scholar
  • 25 Kuwert T, Woesler B, Morgenroth C, Lerch H, Schafers M, Palkovic S, Matheja P, Brandau W, Wassmann H, Schober O. Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine.  J Nucl Med. 1998;  39 23-27
    PubMedSearch in Google Scholar
  • 26 Lanfermann H, Herminghaus S, Pilatus U, Hattingen E, Zanella F E. Bedeutung der 1H-MR-Spektroskopie bei der Differenzialdiagnose und Graduierung intrakranieller Tumoren.  Dtsch Arztebl. 2004;  101 A649-A655
    PubMedSearch in Google Scholar
  • 27 Langen K J, Pauleit D, Coenen H H. [123I]Iodo-α-Methyl-L-Tyrosine: uptake mechanisms and clinical applications.  Nucl Med Biol. 2002;  29 625-631
    CrossrefPubMedSearch in Google Scholar
  • 28 Langen K -J. Amino Acid Transport Studies in Brain Tumors. In: Molecular Nuclear Medicine - The Challenge of Genomics and Proteomics to Clinical Practice. In: Feinendegen LE, Shreeve WW, Eckelman WC, Bahk Y-W, Wagner Jr HN (eds). Springer-Verlag Berlin, Heidelberg 2003, S. 477-485
  • 29 Langen K J, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, Coenen H H, Pauleit D. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications.  Nucl Med Biol. 2006;  33 287-294
    CrossrefPubMedSearch in Google Scholar
  • 30 Le Jeune F P, Dubois F, Blond S, Steinling M. Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies.  J Neurooncol. 2006;  77 177-183
    CrossrefPubMedSearch in Google Scholar
  • 31 Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T, Sasaki T. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging.  Eur J Nucl Med. 2001;  28 1664-1670
    CrossrefPubMedSearch in Google Scholar
  • 32 Pauleit D, Langen K J, Floeth F W, Hautzel H, Riemenschneider M J, Reifenberger G, Shah J, Müller H W. Can the apparent diffusion coefficient be used as a noninvasive parameter to distinguish tumor tissue from peritumoral tissue in cerebral gliomas?.  J Magn Reson Imaging. 2004;  20 758-764
    CrossrefPubMedSearch in Google Scholar
  • 33 Pauleit D, Floeth F, Hamacher K, Riemenschneider M J, Reifenberger G, Müller H W, Zilles K, Coenen H H, Langen K J. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with Magnetic Resonance Imaging Improves the Diagnostic Assessment of Cerebral Gliomas.  Brain. 2005;  128 678-687
    CrossrefPubMedSearch in Google Scholar
  • 34 Plotkin M, Eisenacher J, Bruhn H, Wurm R, Michel R, Stockhammer F, Feussner A, Dudeck O, Wust P, Felix R, Amthauer H. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study.  J Neurooncol. 2004;  70 49-58
    CrossrefPubMedSearch in Google Scholar
  • 35 Pöpperl G, Gotz C, Rachinger W, Schnell O, Gildehaus F J, Tonn J C, Tatsch K. Serial O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma.  Eur J Nucl Med Mol Imaging. 2006;  33 792-800
    CrossrefPubMedSearch in Google Scholar
  • 36 Pöpperl G, Kreth F W, Herms J, Koch W, Mehrkens J H, Gildehaus F J, Kretzschmar H A, Tonn J C, Tatsch K. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?.  J Nucl Med. 2006;  47 393-403
    PubMedSearch in Google Scholar
  • 37 Prigent-Le Jeune F, Dubois F, Perez S, Blond S, Steinling M. Technetium-99m sestamibi brain SPECT in the follow-up of glioma for evaluation of response to chemotherapy: first results.  Eur J Nucl Med Mol Imaging.. 2004;  31 714-719
    CrossrefPubMedSearch in Google Scholar
  • 38 Rachinger W, Goetz C, Pöpperl G, Gildehaus F J, Kreth F W, Holtmannspotter M, Herms J, Koch W, Tatsch K, Tonn J C. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas.  Neurosurgery. 2005;  57 505-511
    CrossrefPubMedSearch in Google Scholar
  • 39 Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B, Bolander H, Bergstrom M, Smits A. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas.  Cancer. 2001;  92 1541-1549
    CrossrefPubMedSearch in Google Scholar
  • 40 Ricci P E, Karis J P, Heiserman J E, Fram E K, Bice A N, Drayer B P. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?.  Am J Neuroradiol. 1998;  19 407-413
    PubMedSearch in Google Scholar
  • 41 Salber D, Stoffels G, Pauleit D, Reifenberger G, Sabel M, Shah N J, Hamacher K, Coenen H H, Langen K J. Differential uptake of 18F-FET and 3H-L-methionine in focal cortical ischemia.  Nucl Med Biol. 2006;  33 1029-1035
    CrossrefPubMedSearch in Google Scholar
  • 42 Saleem A, Brown G D, Brady F, Aboagye E O, Osman S, Luthra S K, Ranicar A S, Brock C S, Stevens M F, Newlands E, Jones T, Price P. Metabolic activation of temozolomide measured in vivo using positron emission tomography.  Cancer Res. 2003;  63 2409-2415
    PubMedSearch in Google Scholar
  • 43 Schillaci O, Filippi L, Manni C, Santoni R. Single-photon emission computed tomography/computed tomography in brain tumors.  Semin Nucl Med. 2007;  37 Review 34-47
    CrossrefPubMedSearch in Google Scholar
  • 44 Semba T, Sugawara Y, Ochi T, Fujii T, Mochizuki T, Ohnishi T. Thallium-201 SPECT in prognostic assessment of malignant gliomas treated with postoperative radiotherapy.  Ann Nucl Med. 2006;  20 287-294
    PubMedSearch in Google Scholar
  • 45 Sun D, Liu Q, Liu W, Hu W. Clinical application of 201Tl SPECT imaging of brain tumors.  J Nucl Med. 2000;  41 5-10
    PubMedSearch in Google Scholar
  • 46 Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.  Eur J Nucl Med Mol Imaging. 2005;  32 39-51
    CrossrefPubMedSearch in Google Scholar
  • 47 Vos M J, Berkhof J, Postma T J, Hoekstra O S, Barkhof F, Heimans J J. Thallium-201 SPECT: the optimal prediction of response in glioma therapy.  Eur J Nucl Med Mol Imaging. 2006;  33 222-227
    CrossrefPubMedSearch in Google Scholar
  • 48 Weckesser M, Langen K J, Rickert C H, Kloska S, Straeter R, Hamacher K, Kurlemann G, Wassmann H, Coenen H H, Schober O. Initial experiences with O-(2-[18F]fluorethyl)-L-tyrosine PET in the evaluation of primary brain tumors.  Eur J Nucl Med. 2005;  32 422-429
    CrossrefPubMedSearch in Google Scholar

Prof. Dr. K.-J. Langen

Institut für Neurowissenschaften und Biophysik - Medizin · Forschungszentrum Jülich

Leo-Brandt-Str.

52425 Jülich

Email: k.j.langen@fz-juelich.de